{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:20:11Z","timestamp":1784308811209,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00259-024-07000-5","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T04:33:57Z","timestamp":1732941237000},"page":"1257-1270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-time diagnosis of sampled lesions in targeted biopsy of prostate Cancer using a novel tracer [64Cu] Cu-DOTA-PSMA-3Q: a pilot preclinical study"],"prefix":"10.1007","volume":"52","author":[{"given":"Jingfeng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxi","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yachao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shina","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6172-9896","authenticated-orcid":false,"given":"Baixuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,30]]},"reference":[{"key":"7000_CR1","doi-asserted-by":"publisher","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2022;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","DOI":"10.3322\/caac.21834"},{"key":"7000_CR2","doi-asserted-by":"publisher","unstructured":"Capasso G, Stefanucci A, Tolomeo A. A systematic review on the current status of PSMA-targeted imaging and radioligand therapy. Eur J Med Chem. 2024;263. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115966.","DOI":"10.1016\/j.ejmech.2023.115966"},{"key":"7000_CR3","doi-asserted-by":"publisher","unstructured":"Jiao J, Zhang J, Li Z, Wen W, Cui C, Zhang Q, et al. Prostate specific membrane antigen positron emission tomography in primary prostate cancer diagnosis: first-line imaging is afoot. Cancer Lett. 2022;548. https:\/\/doi.org\/10.1016\/j.canlet.2022.215883.","DOI":"10.1016\/j.canlet.2022.215883"},{"key":"7000_CR4","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1097\/js9.0000000000001232","volume":"110","author":"N Zeng","year":"2024","unstructured":"Zeng N, Sun J-X, Liu C-Q, Xu J-Z, An Y, Xu M-Y, et al. Knowledge mapping of application of image-guided surgery in prostate cancer: a bibliometric analysis (2013\u20132023). Int J Surg. 2024;110:2992\u20133007. https:\/\/doi.org\/10.1097\/js9.0000000000001232.","journal-title":"Int J Surg"},{"key":"7000_CR5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00259-020-04863-2","volume":"48","author":"L-L Zhang","year":"2020","unstructured":"Zhang L-L, Li W-C, Xu Z, Jiang N, Zang S-M, Xu L-W, et al. 68Ga-PSMA PET\/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study. Eur J Nucl Med Mol Imaging. 2020;48:483\u201392. https:\/\/doi.org\/10.1007\/s00259-020-04863-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7000_CR6","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.2967\/jnumed.119.235333","volume":"61","author":"C Liu","year":"2020","unstructured":"Liu C, Liu T, Zhang Z, Zhang N, Du P, Yang Y, et al. 68Ga-PSMA PET\/CT combined with PET\/Ultrasound-Guided prostate biopsy can diagnose clinically significant prostate Cancer in men with previous negative biopsy results. J Nucl Med. 2020;61:1314\u20139. https:\/\/doi.org\/10.2967\/jnumed.119.235333.","journal-title":"J Nucl Med"},{"key":"7000_CR7","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00345-020-03490-8","volume":"39","author":"YJL Bodar","year":"2020","unstructured":"Bodar YJL, Jansen BHE, van der Voorn JP, Zwezerijnen GJC, Meijer D, Nieuwenhuijzen JA, et al. Detection of prostate cancer with 18F-DCFPyL PET\/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial. World J Urol. 2020;39:2439\u201346. https:\/\/doi.org\/10.1007\/s00345-020-03490-8.","journal-title":"World J Urol"},{"key":"7000_CR8","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.21873\/anticanres.15785","volume":"42","author":"P Pepe","year":"2022","unstructured":"Pepe P, Pepe L, Cosentino S, Ippolito M, Pennisi M, Fraggetta F. Detection rate of 68Ga-PSMA PET\/CT vs. mpMRI targeted biopsy for clinically significant prostate Cancer. Anticancer Res. 2022;42:3011\u20135. https:\/\/doi.org\/10.21873\/anticanres.15785.","journal-title":"Anticancer Res"},{"key":"7000_CR9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4081\/aiua.2022.3.274","volume":"94","author":"P Pepe","year":"2022","unstructured":"Pepe P, Pepe L, Tamburo M, Marletta G, Pennisi M, Fraggetta F. Targeted prostate biopsy: 68Ga-PSMA PET\/CT vs. mpMRI in the diagnosis of prostate cancer. Archivio Italiano Di Urol E Andrologia. 2022;94:274\u20137. https:\/\/doi.org\/10.4081\/aiua.2022.3.274.","journal-title":"Archivio Italiano Di Urol E Andrologia"},{"key":"7000_CR10","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.7150\/thno.95039","volume":"14","author":"J Jiao","year":"2024","unstructured":"Jiao J, Zhang J, Wen W, Qin W, Chen X. Prostate-specific membrane antigen-targeted surgery in prostate cancer: accurate identification, real-time diagnosis, and precise resection. Theranostics. 2024;14:2736\u201356. https:\/\/doi.org\/10.7150\/thno.95039.","journal-title":"Theranostics"},{"key":"7000_CR11","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00259-021-05599-3","volume":"49","author":"DA Ferraro","year":"2021","unstructured":"Ferraro DA, Laudicella R, Zeimpekis K, Mebert I, M\u00fcller J, Maurer A, et al. Hot needles can confirm accurate lesion sampling intraoperatively using [18F]PSMA-1007 PET\/CT-guided biopsy in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging. 2021;49:1721\u201330. https:\/\/doi.org\/10.1007\/s00259-021-05599-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7000_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06833-4","author":"X Luan","year":"2024","unstructured":"Luan X, Niu S, Liu Y, Zhang X, Xu X, Sun S, et al. The first-in-human preclinical evaluation of the new probe [123I]I-PSMA-7 for real-time intraoperative targeted biopsy and SPECT\/CT imaging in prostate cancer. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-06833-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7000_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate Cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-Ligand PET\/CT. J Nucl Med. 2018;59:469\u201378. https:\/\/doi.org\/10.2967\/jnumed.117.198119.","journal-title":"J Nucl Med"},{"key":"7000_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1089\/cbr.2015.1964","volume":"31","author":"B Grubm\u00fcller","year":"2016","unstructured":"Grubm\u00fcller B, Baum RP, Capasso E, Singh A, Ahmadi Y, Knoll P, et al. 64Cu-PSMA-617 PET\/CT imaging of prostate adenocarcinoma: first In-Human studies. Cancer Biotherapy Radiopharmaceuticals. 2016;31:277\u201386. https:\/\/doi.org\/10.1089\/cbr.2015.1964.","journal-title":"Cancer Biotherapy Radiopharmaceuticals"},{"key":"7000_CR15","doi-asserted-by":"publisher","unstructured":"Milot M-C, Benesty OB, Dumulon-Perreault V, Ait-Mohand S, Richard PO, Rousseau \u00c9, et al. 64Cu-DOTHA2-PSMA, a Novel PSMA PET radiotracer for prostate Cancer with a long imaging time window. Pharmaceuticals. 2022;15. https:\/\/doi.org\/10.3390\/ph15080996.","DOI":"10.3390\/ph15080996"},{"key":"7000_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.3196","author":"N Mookerji","year":"2024","unstructured":"Mookerji N, Pfanner T, Hui A, Huang G, Albers P, Mittal R, et al. Fluorine-18 prostate-specific membrane Antigen\u20131007 PET\/CT vs Multiparametric MRI for Locoregional staging of prostate Cancer. JAMA Oncol. 2024. https:\/\/doi.org\/10.1001\/jamaoncol.2024.3196.","journal-title":"JAMA Oncol"},{"key":"7000_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane Antigen Positron Emission Tomography in Advanced prostate Cancer\u2014updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane Antigen-avid lesions: a systematic review and Meta-analysis. Eur Urol. 2020;77:403\u201317. https:\/\/doi.org\/10.1016\/j.eururo.2019.01.049.","journal-title":"Eur Urol"},{"key":"7000_CR18","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","volume":"80","author":"L Emmett","year":"2021","unstructured":"Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The Additive Diagnostic Value of prostate-specific membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the diagnosis of prostate Cancer (PRIMARY): a prospective Multicentre Study. Eur Urol. 2021;80:682\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.002.","journal-title":"Eur Urol"},{"key":"7000_CR19","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.euo.2023.11.008","volume":"7","author":"JP Buteau","year":"2024","unstructured":"Buteau JP, Moon D, Fahey MT, Roberts MJ, Thompson J, Murphy DG, et al. Clinical trial protocol for PRIMARY2: a Multicentre, phase 3, Randomised Controlled Trial investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography\/Computed Tomography in men with negative or Equivocal Multiparametric Magnetic Resonance Imaging for the diagnosis of clinically significant prostate Cancer. Eur Urol Oncol. 2024;7:544\u201352. https:\/\/doi.org\/10.1016\/j.euo.2023.11.008.","journal-title":"Eur Urol Oncol"},{"key":"7000_CR20","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1007\/s00259-021-05426-9","volume":"48","author":"T Liu","year":"2021","unstructured":"Liu T, Liu C, Zhang Z, Zhang N, Guo X, Xia L, et al. 64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:4508\u201316. https:\/\/doi.org\/10.1007\/s00259-021-05426-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7000_CR21","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1007\/s00259-021-05501-1","volume":"48","author":"JH R\u00fcschoff","year":"2021","unstructured":"R\u00fcschoff JH, Ferraro DA, Muehlematter UJ, Laudicella R, Hermanns T, Rodewald A-K, et al. What\u2019s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. Eur J Nucl Med Mol Imaging. 2021;48:4042\u201353. https:\/\/doi.org\/10.1007\/s00259-021-05501-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7000_CR22","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.7150\/thno.44584","volume":"10","author":"DA Ferraro","year":"2020","unstructured":"Ferraro DA, R\u00fcschoff JH, Muehlematter UJ, Kranzb\u00fchler B, M\u00fcller J, Messerli M, et al. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga-PSMA-11-PET. Theranostics. 2020;10:6082\u201394. https:\/\/doi.org\/10.7150\/thno.44584.","journal-title":"Theranostics"},{"key":"7000_CR23","doi-asserted-by":"publisher","unstructured":"Zhang C, Tu X, Dai J, Xiong X, Cai D, Yang L, et al. Efficacy and safety of the new biopsy strategy combining 6-core systematic and 3-core MRI-targeted biopsy in the detection of prostate cancer: study protocol for a randomized controlled trial. Front Surg. 2023;9. https:\/\/doi.org\/10.3389\/fsurg.2022.1058288.","DOI":"10.3389\/fsurg.2022.1058288"},{"key":"7000_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.eururo.2022.03.002","volume":"82","author":"HA de Barros","year":"2022","unstructured":"de Barros HA, van Oosterom MN, Donswijk ML, Hendrikx JJMA, Vis AN, Maurer T, et al. Robot-assisted prostate-specific membrane Antigen\u2013radioguided salvage surgery in recurrent prostate Cancer using a DROP-IN Gamma Probe: the first prospective feasibility study. Eur Urol. 2022;82:97\u2013105. https:\/\/doi.org\/10.1016\/j.eururo.2022.03.002.","journal-title":"Eur Urol"},{"key":"7000_CR25","doi-asserted-by":"publisher","first-page":"548","DOI":"10.2967\/jnumed.123.267075","volume":"65","author":"A-C Berrens","year":"2024","unstructured":"Berrens A-C, Sorbi MA, Donswijk ML, de Barros HA, Azargoshasb S, van Oosterom MN, et al. Strong correlation between SUVmaxon PSMA PET\/CT and numeric Drop-In \u03b3-Probe Signal for intraoperative identification of prostate Cancer lesions. J Nucl Med. 2024;65:548\u201354. https:\/\/doi.org\/10.2967\/jnumed.123.267075.","journal-title":"J Nucl Med"},{"key":"7000_CR26","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.eururo.2015.04.034","volume":"68","author":"T Maurer","year":"2015","unstructured":"Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A, et al. Prostate-specific membrane Antigen\u2013radioguided surgery for metastatic lymph nodes in prostate Cancer. Eur Urol. 2015;68:530\u20134. https:\/\/doi.org\/10.1016\/j.eururo.2015.04.034.","journal-title":"Eur Urol"},{"key":"7000_CR27","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.2967\/jnumed.119.240424","volume":"61","author":"C Darr","year":"2020","unstructured":"Darr C, Harke NN, Radtke JP, Yirga L, Kesch C, Grootendorst MR, et al. Intraoperative 68Ga-PSMA Cerenkov Luminescence Imaging for Surgical margins in Radical Prostatectomy: a feasibility study. J Nucl Med. 2020;61:1500\u20136. https:\/\/doi.org\/10.2967\/jnumed.119.240424.","journal-title":"J Nucl Med"},{"key":"7000_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1053\/j.semnuclmed.2023.07.001","volume":"54","author":"MR Jochumsen","year":"2024","unstructured":"Jochumsen MR, Bouchelouche K. PSMA PET\/CT for primary staging of prostate Cancer - an updated overview. Semin Nucl Med. 2024;54:39\u201345. https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.07.001.","journal-title":"Semin Nucl Med"},{"issue":"2","key":"7000_CR29","first-page":"40","volume":"7","author":"C Cui","year":"2017","unstructured":"Cui C, Hanyu M, Hatori A, Zhang Y, Xie L, Ohya T, et al. Synthesis and evaluation of [64Cu]PSMA-617 targeted for prostate-specific membrane antigen in prostate cancer. Am J Nucl Med Mol Imaging. 2017;7(2):40\u201352.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"4","key":"7000_CR30","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1021\/bc990167l","volume":"11","author":"LA Bass","year":"2000","unstructured":"Bass LA, Wang M, Welch MJ, Anderson CJ. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem. 2000;11(4):527\u201332. https:\/\/doi.org\/10.1021\/bc990167l.","journal-title":"Bioconjug Chem"},{"key":"7000_CR31","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1021\/acs.jmedchem.1c00117","volume":"64","author":"X Zhang","year":"2021","unstructured":"Zhang X, Wu Y, Zeng Q, Xie T, Yao S, Zhang J, et al. Synthesis, preclinical evaluation, and first-in-human PET study of Quinoline-Containing PSMA tracers with decreased renal excretion. J Med Chem. 2021;64:4179\u201395. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00117.","journal-title":"J Med Chem"},{"key":"7000_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/mnm.0000000000001564","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zhang X, Liu J, Zhang J, Xu B. Prospective intraindividual comparison of 18F-PSMA-7Q and 18F-DCFPyL PET\/CT in patients with newly diagnosed prostate cancer. Nucl Med Commun. 2022. https:\/\/doi.org\/10.1097\/mnm.0000000000001564.","journal-title":"Nucl Med Commun"},{"key":"7000_CR33","doi-asserted-by":"publisher","first-page":"812","DOI":"10.2967\/jnumed.113.133850","volume":"55","author":"C Qin","year":"2014","unstructured":"Qin C, Liu H, Chen K, Hu X, Ma X, Lan X, et al. Theranostics of malignant melanoma with 64CuCl2. J Nucl Med. 2014;55:812\u20137. https:\/\/doi.org\/10.2967\/jnumed.113.133850.","journal-title":"J Nucl Med"},{"issue":"6","key":"7000_CR34","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1021\/jm030383m","volume":"47","author":"CA Boswell","year":"2004","unstructured":"Boswell CA, Sun X, Niu W, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem. 2004;47(6):1465\u201374. https:\/\/doi.org\/10.1021\/jm030383m.","journal-title":"J Med Chem"},{"key":"7000_CR35","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2967\/jnumed.107.039487","volume":"48","author":"JC Garrison","year":"2007","unstructured":"Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, Jurisson SS, et al. In vivo evaluation and small-animal PET\/CT of a prostate Cancer Mouse Model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA Chelation systems. J Nucl Med. 2007;48:1327\u201337. https:\/\/doi.org\/10.2967\/jnumed.107.039487.","journal-title":"J Nucl Med"},{"key":"7000_CR36","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/bju.14089","volume":"121","author":"J Mischinger","year":"2018","unstructured":"Mischinger J, Kaufmann S, Russo GI, Harland N, Rausch S, Amend B, et al. Targeted vs systematic robot-assisted transperineal magnetic resonance imaging\u2010transrectal ultrasonography fusion prostate biopsy. BJU Int. 2018;121:791\u20138. https:\/\/doi.org\/10.1111\/bju.14089.","journal-title":"BJU Int"},{"key":"7000_CR37","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1148\/radiol.204066","volume":"303","author":"R Kumar","year":"2022","unstructured":"Kumar R, Singh SK, Mittal BR, Vadi SK, Kakkar N, Singh H, et al. Safety and Diagnostic yield of 68Ga prostate-specific membrane Antigen PET\/CT-guided robotic-assisted Transgluteal Prostatic Biopsy. Radiology. 2022;303:392\u20138. https:\/\/doi.org\/10.1148\/radiol.204066.","journal-title":"Radiology"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-07000-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-07000-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-07000-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:54:53Z","timestamp":1739962493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-07000-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,30]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["7000"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-07000-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,30]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Chinese PLA General Hospital (approval of No. S2023-208-02, Registration number of ChiCTR2300072655).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have read this manuscript and would like to have it considered exclusively for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}